LIFEVANTAGE CORP Payments of Debt Issuance Costs
LIFEVANTAGE CORP (LFVN) reported Payments of Debt Issuance Costs of $2.70 million for the 12-month period ending 2016-06-30, per its 10-K filed 2016-12-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2017-09-07
- LIFEVANTAGE CORP payments of debt issuance costs for fiscal 2016 was $2.70M.
| Period end | Payments of Debt Issuance Costs 1 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|
| 2016-06-30 | $2.70M 10-K · filed 2016-12-12 | |
| 2013-10-31 | $2.70M 10-K · filed 2017-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |